Abstract:Abstract Background Clostridium butyricum (C. butyricum) is a strictly anaerobic, Gram-positive, spore-forming bacillus named for its capacity to produce high amounts of butyric acid. Some strains of C. butyricum involved in infectious diseases are known to be currently used as probiotics in Asia. Especially in Japan, MIYA-BM® is one of the probiotics commonly used as prescription drugs and it contains C. butyricum MIYAIRI 588 strain (CBM588). On the other hand, other strains involved in infectious diseases are known to be pathogenic. Bacteremia due to C. butyricum is a rare condition, and the prevalence, clinical features, and bacteriological and genetic origins of the condition are unknown. Methods We conducted a retrospective cohort study of medical records of patients to detect cases of C. butyricum bacteremia in Osaka University Hospital from September 19, 2011, to February 5, 2023. We analyzed the whole-genome sequencing of C. butyricum strains from positive blood culture samples, as well as strains from the probiotic MIYA-BM®. We also analyzed to determine the homology between these strains. Results Out of a total of 6576 positive blood culture samples, we detected five cases (0.08%) of bacteremia due to C. butyricum. Whole-genome analysis showed that the genes of each strain had only 1-33 mutations compared to the genes of the CBM588 strain, identifying them as the same clone derived from MIYA-BM®. The detail of case characteristics is shown in Table 1. All patients had bacteremia during hospitalization, with two male and three female patients. Four patients had concurrent use of MIYA-BM®. Four patients had immunocompromised conditions, and two patients had end-stage kidney disease on dialysis. All patients had a fever and abdominal symptoms such as diarrhea and pain. A patient with non-occlusive mesenteric ischemia died within 90 days.Table.Detailed clinical and microbiological information on five cases. Conclusion All C. butyricum strains detected from blood cultures in our hospital were derived from probiotics. Although C. butyricum bacteremia is rare condition, the use of MIYA-BM® use in hospitalized patients with multiple medical interventions is considered to cause C. butyricum bacteremia. Disclosures All Authors: No reported disclosures

Probiotics-related Clostridium butyricum bacteraemia after COVID-19, confirmed by whole-genome sequencing

Gut Microbiota Improves Prognostic Prediction in Critically Ill COVID-19 Patients Alongside Immunological and Hematological Indicators

233. All Clostridium butyricum strains isolated from blood cultures were derived from probiotics: a single-centre retrospective study

Dynamics of the Upper Respiratory Tract Microbiota and Its Association with Fatality in COVID-19 Patients

Gut Microbiota Imbalance in Colorectal Cancer Patients, the Risk Factor of COVID-19 Mortality

Dysbiosis of gut microbiota in patients with severe COVID-19

The role of probiotics in coronavirus disease-19 infection in Wuhan: A retrospective study of 311 severe patients

The Volatile and Heterogeneous Gut Microbiota Shifts of COVID‐19 Patients over the Course of a Probiotics‐assisted Therapy

Probiotics improve symptoms of patients with COVID-19 through gut-lung axis: a systematic review and meta-analysis

The Influence of Probiotic Lactobacilli on COVID-19 and the Microbiota

Association of Probiotic Clostridium butyricum Therapy with Survival and Response to Immune Checkpoint Blockade in Patients with Lung Cancer

Probiotics for preventing or treating COVID-19; a systematic review of research evidence and meta-analyses of efficacy for preventing death, severe disease, or disease progression

IMPORTANCE OF PROBIOTICS IN THE PREVENTION AND TREATMENT OF COVID-19

Probiotics and COVID-19 – Authors' Reply

The effect of microbiome therapy on COVID-19-induced gut dysbiosis: A narrative and systematic review

Potential Roles for Probiotics in the Treatment of COVID-19 Patients and Prevention of Complications Associated with Increased Antibiotic Use

Gut Microbiome and COVID 19 Role of Probiotics on Gut Lung Axis

Immunomodulatory fecal metabolites are associated with mortality in COVID-19 patients with respiratory failure

The Butyrate-Producing Bacterium Clostridium butyricum Suppresses Clostridioides difficile Infection via Neutrophil- and Antimicrobial Cytokine-Dependent but GPR43/109a-Independent Mechanisms

Bacterial and Fungal Gut Dysbiosis and Clostridium difficile in COVID-19: A Review

Effectiveness of immobilized probiotics for complex therapy of novel coronavirus infection COVID-19 in hospital settings